Navigation Links
UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt
Date:2/6/2012

CENTERVILLE, Mass., Feb. 6, 2012 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCBB: UVFTD) (the "Company") is pleased to announce it is ahead of schedule in its continuing program to eliminate all debt. On February 3, 2012, the Company notified Asher Enterprises, LLC, that the remaining and final convertible note, in the amount of $32,500 would be paid off in cash.

"The progress we have made in the last twelve months is nothing short of extraordinary," said Jack Lennon, President of UV Flu. "One year ago, our notes and accounts payable amounted to almost one-million dollars. With the payoff of this note, the $118k note and other reductions in notes and accounts payable, we anticipate having total debt and accounts payable at levels 90-95% below that of a year ago."

"Our program with furniture stores continues to move forward, with display kiosks and advertising materials now in production," said Mr. Lennon. "We are shipping product to India, Oman, Tunisia, and are still working out details with distribution in China and Italy. We are aggressively pursuing American hospitals with a variety of distributors, including Grainger, Inc, and expect 2012 sales to be significantly higher."

Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's  ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.

About UV Flu Technologies, Inc. (OTCBB: UVFT)

UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOCs (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.)  The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

In addition, the Company's RxAir subsidiary in Dallas, TX, makes one of the world's finest lines of hospital-grade HEPA filtration products. The RX-3000, the Company's main product, is currently in almost 450 hospitals internationally, is FDA cleared as a Class II Medical Device, and has been shown to capture 99.99% of all airborne contaminants. The Company's product lines are in Hospitals, government buildings, casinos and restaurants around the world.

For more information, visit: www.uvflutech.com. Or www.rxair.com

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.

John J. Lennon,  President & CEO

Investor Information:
Toll-Free: 1-877-358-5455
Web: www.uvflutech.com


'/>"/>
SOURCE UV Flu Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
2. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
3. Cell Therapy - Technologies, Markets and Companies
4. Life Technologies to Present at Upcoming Investment Conferences in February
5. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
6. Life Technologies Announces Redemption of 1.5% Convertible Senior Notes Due 2024
7. Ion Proton™ Sequencer - Inventor, Dr. M. Jonathan Rothberg and Life Technologies CEO, Greg Lucier, Available for Interviews at CES Today
8. Life Technologies Plant in Austin, Texas Named One of IndustryWeeks Top Ten Best Plants for 2011
9. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
10. Cytogenetics - Technologies, Markets and Companies
11. BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... Parsippany, NJ (PRWEB) , ... June 20, 2017 , ... ... OHAUS makes the transition from being a trusted supplier in the weighing industry, to ... including cell extractions, ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for ...
(Date:6/19/2017)... , ... June 19, 2017 , ... ... all service activities supporting EDETEK’s products including training, implementation, support, and client process ... his new role. He has previously held leadership roles for service providers and ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting has been solving ... of the biggest challenges faced by life sciences, biotech and pharmaceuticals companies today is ... Kati Abraham , who is well known in the industry and brings significant ...
(Date:6/16/2017)... Lexington, Massachusetts (PRWEB) , ... June 16, 2017 ... ... in medical device compliance and commercialization, has just announced two more sessions of ... of the series will focus on the world of online templates for design ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):